PDCD1 and hepatocellular carcinoma: [178] announced the results of the PLATIC clinical trial, which investigated PD‐1 inhibitors combined with lenvatinib and TACE–hepatic arterial infusion chemotherapy (HAIC) as a conversion treatment for initially unresectable HCC patients.